Clinical Setback Sparks Drastic Overhaul at IO Biotech

Restructuring Plan Follows Regulatory Disappointment

IO Biotech shares continue to experience extreme price swings following a critical regulatory development. The catalyst for this volatility was a recommendation from the U.S. Food and Drug Administration advising the company against submitting a marketing application for its promising cancer vaccine candidate, Cylembio. This regulatory setback triggered an immediate corporate response, including a workforce reduction affecting approximately half of all employees.

The biopharmaceutical company received the FDA’s negative assessment on September 29. Regulators determined that data from the pivotal Phase 3 trial IOB-013 failed to meet standards for approval, despite the study demonstrating clinical improvement in progression-free survival. The results narrowly missed statistical significance, with a p-value of 0.056.